Zacks upgrades CONMED shares — 5 quick facts

Zacks analysts upgraded CONMED shares from a “hold” rating to a “buy” rating, according to EMQ News & Analysis.

Advertisement

Here are five quick facts:

 

1. Zacks has a $45 price objective on CONMED stock.

 

2. On Jan. 14, CONMED shares fell 2.4 percent.

 

3. The company has a 50-day moving average of $42.10.

 

4. The 200-day moving average is $48.62.

 

5. CONMED has a market cap of $1.08 billion.

 

More articles on devices:
SeaSpine, K2M, Smith & Nephew & more: 19 key notes
DeGen Medical launches Hyper-C Anterior Cervical Plate System: 4 key notes
Medical Compression Systems seeks buyer: 3 things to know

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.